Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial ( MAST) trial
BJU International · 2026-08 · 138 (2) · 276-284
DOI: 10.1111/bju.70303 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 06.05.2026. Verfasst von Seyed Hossein Hosseini Sharifi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Sylvester Comprehensive Cancer Center, Desai Sethi Urology Institute at the University of Miami Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Multiparametric Magnetic Resonance Imaging, Watchful Waiting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Objectives
To examine the role of multiparametric magnetic resonance imaging (mpMRI) in enhancing prostate cancer (PCa) detection and selecting candidates for active surveillance (AS), given that its utility in monitoring disease progression remains unclear. Patients and Methods The Miami Active Surveillance Trial (MAST) is a prospective trial of men undergoing serial mpMRI and biopsies on AS for PCa. Participants had annual mpMRI with MRI‐targeted and systematic biopsies at confirmatory (12–18 months) and subsequent intervals (12, 24, and 36 months). Grade progression was defined as an upgrade from Grade Group (GG) 1 to GG ≥2 or GG 2 to GG ≥3. The performance of MRI was evaluated at baseline (prior to confirmatory biopsy) and on subsequent biopsies for association with grade progression. Fine and Gray competing‐risk models evaluated MRI for predicting grade progression after controlling for risk factors.
Results
Among 205 men, 79 (38.5%) had grade progression at the conclusion of the trial (36 months), with 40 (19.5%) men having grade progression at confirmatory biopsy, and the remaining 39 (2.0–9.8%/year) progressing on subsequent biopsies. A Prostate Imaging‐Reporting And Data System (PI‐RADS) score of 4 or 5 (vs no suspicious lesions or PI‐RADS 1 and 2) on baseline MRI (prior to confirmatory biopsy) was an independent predictor of grade progression on confirmatory biopsy (Gray's test P < 0.001), with volume progression treated as a competing risk. At 36 months, MRI‐only surveillance would have avoided 45% of biopsies but missed 32% of progression events.
Conclusion
Pre‐confirmatory biopsy MRI independently predicted grade progression on confirmatory and subsequent biopsies during AS; however, false positives and negatives still occur highlighting the need for periodic biopsy of the prostate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sylvester Comprehensive Cancer Center, Desai Sethi Urology Institute at the University of Miami Miller School of Medicine, Miami, FL, USA.
- Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD), Davie, FL, USA.
- Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
- Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
- Department of Pathology, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
- Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
ORCID-Profile: Jonathan T Ryan, Archan Khandekar, Chad R Ritch
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Sharifi, S. H. H., Williams, A., Ryan, J. T., Ajami, T., Nativ, O. F., Han, S., Reis, I. M., Soodana-Prakash, N., Khandekar, A., Swain, S., Kryvenko, O. N., Stoyanova, R., Pollack, A., Castillo, P. R., Nahar, B., Ritch, C. R., Kava, B., Gonzalgo, M. L., Parekh, D. J., & Punnen, S. (2026). Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial ( MAST) trial. BJU International, 138(2), 276-284. https://doi.org/10.1111/bju.70303
Vancouver
Sharifi SHH, Williams A, Ryan JT, Ajami T, Nativ OF, Han S, et al. Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial ( MAST) trial. BJU International. 2026;138(2):276-284. doi:10.1111/bju.70303
BibTeX
@article{Sharifi2026,
author = {Sharifi, Seyed Hossein Hosseini and Williams, Adam and Ryan, Jonathan T and Ajami, Tarek and Nativ, Omri Falik and Han, Sunwoo and Reis, Isildinha M and Soodana-Prakash, Nachiketh and Khandekar, Archan and Swain, Sanjaya and Kryvenko, Oleksandr N and Stoyanova, Radka and Pollack, Alan and Castillo, Patricia R and Nahar, Bruno and Ritch, Chad R and Kava, Bruce and Gonzalgo, Mark L and Parekh, Dipen J and Punnen, Sanoj},
title = {Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial ( MAST) trial},
journal = {BJU International},
year = {2026},
volume = {138},
number = {2},
pages = {276--284},
doi = {10.1111/bju.70303}
}
EUVIMED